Medicine’s Big Bottleneck

Medicine’s Big Bottleneck
If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.


Comments are closed.

Biotechblog